WO1998050421A1 - Analgesic peptidomimetic compounds - Google Patents
Analgesic peptidomimetic compounds Download PDFInfo
- Publication number
- WO1998050421A1 WO1998050421A1 PCT/SE1998/000826 SE9800826W WO9850421A1 WO 1998050421 A1 WO1998050421 A1 WO 1998050421A1 SE 9800826 W SE9800826 W SE 9800826W WO 9850421 A1 WO9850421 A1 WO 9850421A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- phenyl
- alkyl
- amino
- mmol
- Prior art date
Links
- 0 *C(*c1ccccc1)C(O)=O Chemical compound *C(*c1ccccc1)C(O)=O 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- MCODLPJUFHPVQP-GFCCVEGCSA-N CC(C)(C)OC(N[C@H](CCc1ccccc1)C(O)=O)=O Chemical compound CC(C)(C)OC(N[C@H](CCc1ccccc1)C(O)=O)=O MCODLPJUFHPVQP-GFCCVEGCSA-N 0.000 description 1
- ANUAREQQVOCYBA-MRVPVSSYSA-N CC[C@H](CCC[n]1c([N+]([O-])=O)ncc1)C(O)=O Chemical compound CC[C@H](CCC[n]1c([N+]([O-])=O)ncc1)C(O)=O ANUAREQQVOCYBA-MRVPVSSYSA-N 0.000 description 1
- VQBUFVSETAVKMZ-PDYHCXRVSA-N CN[C@@H](Cc(cc1)ccc1O)C(N[C@H](CCCNC(N)=N)C(NC(Cc1ccccc1)C(O)=O)=O)=O Chemical compound CN[C@@H](Cc(cc1)ccc1O)C(N[C@H](CCCNC(N)=N)C(NC(Cc1ccccc1)C(O)=O)=O)=O VQBUFVSETAVKMZ-PDYHCXRVSA-N 0.000 description 1
- OBSIQMZKFXFYLV-QMMMGPOBSA-N N[C@@H](Cc1ccccc1)C(N)=O Chemical compound N[C@@H](Cc1ccccc1)C(N)=O OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 description 1
- JTTHKOPSMAVJFE-SECBINFHSA-N N[C@H](CCc1ccccc1)C(O)=O Chemical compound N[C@H](CCc1ccccc1)C(O)=O JTTHKOPSMAVJFE-SECBINFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention is related to compounds that exhibit analgesic activity and in particular compounds exhibiting analgesia due to their opioid receptor affinity.
- the second, ⁇ shows enhanced selectivity for enkephalin-like peptides.
- the third, K exhibits equal affinity for either group of the above ligands and preferential affinity for dyn ⁇ rphin.
- the ⁇ - receptors seem to be more involved with analgesic effects.
- the ⁇ -receptors appear to deal with behavioral effects, although the ⁇ and the K-receptors may also mediate analgesia.
- Each opioid receptor when coupled with an opiate, causes a specific biological response unique to that type of receptor.
- an opiate activates more than one receptor, the biological response for each receptor is affected, thereby producing side effects.
- opiates, opioid peptides, and analogs thereof have either failed to demonstrate, or have demonstrated only a limited degree of specificity and selectivity for the type of receptor, or receptors, to which they bind.
- analgesic opioids The primary site of action of analgesic opioids is the central nervous system (CNS) .
- CNS central nervous system
- Conventional narcotic analgesics are normally quite hydrophobic and thus are extremely well-suited to permeate lipid membranes, such as the blood-brain barrier. Due to this physical capability, analgesics tend to bind with opioid receptors within the central nervous system in the brain. However, they do not necessarily bind with a homogeneous receptor subtype. This binding causes medically undesirable side effects to occur.
- opioid analgesics acting principally through opioid receptors in the peripheral nervous system would not be expected to cause similar unwanted side effects as those side effects associated with opioid analgesics affecting the central nervous system.
- non-steroidal anti-inflammatory agents such as aspirin, ibuprofen, and ketorolac.
- these agents do not interact with opioid receptors but are known to inhibit cyclooxygenase and attenuate prostaglandin synthesis.
- These weak analgesics do not have centrally mediated side effects, but they can cause other side effects such as ulcerations of the gastro-intestinal tract.
- compounds that exhibit analgesic activity In particular there is a need for compounds that interact with opioid receptors and more particularly with ⁇ - opioid receptors.
- the present invention provides novel peptidic compounds which act peripherally and are selective for ⁇ -opioid receptors, the compounds represented by formula (I) :
- R. is selected from H, C._ 4 alkyl and C._ 4 acyl ;
- R 2 to R 5 are independently selected from H, OH, halogen, C- . . 4 alkyl and C._ 4 alkoxy;
- R 6 and R 7 are independently selected from H and C x . 4 alkyl;
- R discomfort is H or C 1 _ alkyl;
- n is an integer from 0 to 2 ;
- X is selected from group consisting of (Ila) and (lib)
- R 9 is H, OH, C._ 4 alkyl, NH 2 , or NH-N0 2 ;
- compositions comprising compounds of the present invention and pharmaceutically acceptable carriers, diluents or adjuvants.
- a method of agonizing or activating opioid receptors in a mammal comprising administering to said mammal an opi ⁇ id receptor agonizing or activating amount of a compound or composition of the invention.
- a method of treating pain in a mammal comprising administering to said mammal an analgesic amount of a compound or composition of the invention.
- the present invention provides opioid receptor binding compounds of formula (I)
- R. to R 8 , X and Y are as defined above.
- alkyl represents straight chain, branched chain, or cyclic hydrocarbon moieties, which are optionally substituted by one or more halogen, hydroxyl or amino (NR G R 7 ) groups.
- cycloalkyl refers to a cyclic alkyl group of 4 to 8 members optionally containing unsaturated bonds and/or heteroatoms N, 0 or S .
- Preferred cycloalkyl groups include cyclopentyl, cyclohexyl, and cycloheptyl and is most preferably cyclohexyl.
- aryl as used herein represents a 6 to 12 member aromatic carbocycle such as phenyl and naphthyl or a heterocycle such as pyran, pyridine, quinoline, isoquinoline, indole, benzopyran or benzothiazole .
- X is the group ( I la)
- R 10 to R 12 are as previously defined.
- Z may be 0 or S thereby forming an oxazole or thiazole ring and is preferably N forming an imidazole ring.
- R 10 is H, NH 2 or N0 2 while R X1 and R 12 are both H and in a most preferred embodiment each of R 10 to R 12 are H.
- X is the group (lib)
- R 9 is H, OH, C. _ 4 alkyl , NH 2 or NH-N0 2 .
- R 9 is NH 2 or NH-N0 2 and most preferably NH 2 .
- the group Y is selected from -CHR 13 -C (0) -NR 6 R 7 , -CHR 13 -
- R 13 is cycloalkyl, aryl , cycloalkyl-Ci.,, alkyl or aryl-C-_ 4 alkyl optionally substituted with OH, halogen, NR 6 R 7 , C- . . 4 alkyl or C ⁇ alkoxy;
- R 14 is H, OH, halogen, NR 6 R 7 , c.. 4 alkyl or C 1-4 alkoxy; and
- m is an integer from 0 to 5.
- R 13 is C._ 4 alkyl i.e.
- a methylene group substituted with an optionally substituted aryl or cycloalkyl group is optionally substituted phenyl, naphthyl , pyridinyl or quinolinyl and said cycloalkyl group is optionally substituted cyclohexyl.
- Preferred aryl substituents are OH, halogen or C j. _ 4 alkyl. More preferably said aryl group is phenyl optionally substituted with halogen and most preferably phenyl optionally substituted at the para-position with fluorine (F) .
- m is preferably 1-5
- R 14 is H, OH, halogen, C._ 4 alkyl or NR 6 R 7 and aryl and cycloalkyl are as previously defined. More preferably, m is 3-5 and no more than one R 14 is OH or NH 2 and most preferably, m is 3 , no more than one R 14 is OH, and aryl is a phenyl group and cycloalkyl is cyclohexyl.
- R x is H, C x _ 4 alkyl or C._ 4 acyl .
- R. is H, methyl or acetyl and most preferably H.
- R 2 to R 5 are independently selected from H, OH, halogen, C._ 4 alkyl, and C._ 4 alkoxy.
- R 2 to R 5 are independently H, OH, methyl or methoxy. More preferably R 2 and R 5 are both H while R 3 and R 4 are both H or methyl, and most preferably R 2 and R 5 are H while R 3 and R 4 are both methyl .
- R s and R 7 are independently selected from H and C x _ 4 alkyl .
- R 6 and R 7 are independently H, methyl or ethyl and most preferably are both H.
- R Pain is H or C-. 4 alkyl .
- R a is H or methyl and most preferably H.
- n is an integer from 0 to 2.
- n is 1 or 2 and most preferably 1.
- the compounds of the present invention are preferably selected from the group consisting of:
- the compounds of the present invention are more preferably selected from the group consisting of:
- compositions comprising compounds of the present invention and derivatives thereof, in combination with pharmaceutically acceptable carriers diluents or adjuvants.
- derivative is meant any pharmaceutically acceptable salt, ester, or salt of such ester, of compounds of formula (I) or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) compounds of formula (I) or an active metabolite or residue thereof.
- compounds of formula (I) may contain one or more chiral centers and thus exist in the form of different isomers, optical isomers (i.e. (+) or (-) enantiomers) and mixtures thereof including racemic mixtures . All such isomers, enantiomers and mixtures thereof including racemic mixtures are included within the scope of the invention.
- the chiral carbon atom from which substituent X depends may have an R or S configuration.
- the chiral carbon atom from which the phenyl group substituted with substituents R. to R 5 depends may be in either R or S configuration as well as any chiral carbon atom that may be incorporated in substituent Y.
- Solid phase synthesis involves the stepwise addition of amino acid residues (of either D or L configuration) to a growing peptide chain that is linked to an insoluble (solid) support or matrix, such as polystyrene.
- the C- erminal residue of the targeting peptide is first anchored to a commercially available support with its amino group protected with an N-protecting agent such as a fluorenylmethoxycarbonyl (FMOC) group.
- FMOC fluorenylmethoxycarbonyl
- the amino protecting group is removed with suitable deprotecting agents such as piperidine and the next amino acid residue (in N- protected form) is added with a coupling agent such as dicyclocarbodiimide (DCC) .
- a coupling agent such as dicyclocarbodiimide (DCC)
- DCC dicyclocarbodiimide
- the reagents are washed from the support with a suitable reagent such as trifluoroacetic acid (TFA) .
- Solution phase synthesis of compounds of the invention may be achieved by coupling individual amino acids or derivatives thereof in the following stepwise manner. a) Intermediates (i) and (ii) are coupled in presence of a suitable activating ester agent such as DCC or EDCI to give intermediate (iv) .
- a suitable activating ester agent such as DCC or EDCI
- the N-terminus of (i) is amino-protected with a suitable amino-protecting agent Pr such as Boc, Fmoc or Cbz and the C-terminus of (ii) is protected with a suitable carboxy protecting group Pr' such as benzyl; b) the carboxyl or protecting group Pr' of (iv) is removed with a suitable reagent, for example palladium H 2 catalyst when Pr' is benzyl; c) the carboxyl-deprotected intermediate (iv) is coupled with (iii) in the presence of a suitable ester activating agent to give intermediate (v) ; d) Intermediate (v) is amino-deprotected with a suitable deprotecting agent such as TFA when Pr is Boc, piperidine when Pr is Fmoc, or palladium hydrogenation when Pr is Cbz, to give final compound (I) .
- a suitable amino-protecting agent such as Boc, Fmoc or Cbz
- Pr' carboxy protecting group
- Pr'
- compound of formula (I) is prepared by stepwise addition of amino acid derivatives in the reverse order of scheme I as illustrated in scheme II.
- Intermediates (ii') and (iii') are coupled in the presence of a suitable activating ester agent to give intermediate (iv') .
- the N-terminus of (ii') is protected with a suitable amino protecting agent Pr;
- the amino protecting group Pr of (iv ) is removed with a suitable reagent;
- the amino-deprotected intermediate (iv' ) is coupled with
- Suitable protecting groups i.e. amino, carboxyl or hydroxyl protecting groups, are well known in the field of peptide synthesis and are described in detail in T.W. Greene, Protective Groups In Organic Synthesis, (John Wiley & Sons, 2 e edition 1991) .
- the appropriate protecting group for a particular synthetic scheme will depend on many factors, including the presence of other reactive functional groups and the reaction conditions desired for removal are well known by persons skilled in the art of peptide chemistry.
- compositions which comprise a pharmaceutically effective amount of a compound of the invention, or pharmaceutically acceptable salts thereof, and preferably, a pharmaceutically acceptable carrier, diluent or adjuvant.
- pharmaceutically effective amount is the amount of compound required upon administration to a mammal in order to induce analgesia.
- opioid receptor agonizing amount refers to the amount of compound administered to a mammal necessary to bind and/or activate opioid receptors in vivo.
- Therapeutic methods of this invention comprise the step of treating patients in a pharmaceutically acceptable manner with those compounds or compositions.
- Such compositions may be in the form of tablets, capsules, caplets, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions .
- a composition of the invention is in the form of a unit dose.
- the unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients.
- binding agents such as acacia, gelatin, sorbitol, or polyvinylpyrolidone
- fillers such as lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
- tabletting lubricants such as magnesium stearate
- disintegrants such as starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose
- pharmaceutically acceptable wetting agents such as sodium lauryl sulphate .
- the compounds may be administered orally in the form of tablets, capsules, or granules containing suitable excipients such as starch, lactose, white sugar and the like.
- the compounds may be administered orally in the form of solutions which may contain coloring and/or flavoring agents .
- the compounds may also be administered sublingually in the form of tracheas or lozenges in which each active ingredient is mixed with sugar or corn syrups, flavoring agents and dyes, and then dehydrated sufficiently to make the mixture suitable for pressing into solid form.
- the solid oral compositions may be prepared by conventional methods of blending, filling, tableting, or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
- the tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
- Liquid oral preparations may be in the form of emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may or may not contain conventional additives.
- suspending agents such as sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel, or hydrogenated edible fats
- emulsifying agents such as sorbitan monooleate or acaci
- non-aqueous vehicles which may include edible oils), such as almond oil, fractionated coconut oil, oily esters selected from the group consisting of glycerine, propylene glycol, ethylene glycol, and ethyl alcohol
- preservatives for instance methyl para-hydroxybenzoate, ethyl para- hydroxybenzoate, n-propyl parahydroxybenzoate, or n-butyl parahydroxybenzoate of sorbic
- the compounds may be injected parenterally; this being intramuscularly, intravenously, or subcutaneously .
- the compound may be used in the form of sterile solutions containing other solutes, for example, sufficient saline or glucose to make the solution isotonic.
- fluid unit dosage forms may be prepared by utilizing the compound and a sterile vehicle, and, depending on the concentration employed, may be either suspended or dissolved in the vehicle.
- the compound Once in solution, the compound may be injected and filter sterilized before filling a suitable vial or ampoule and subsequently sealing the carrier or storage package.
- Adjuvants such as a local anesthetic, a preservative or a buffering agent, may be dissolved in the vehicle prior to use.
- Stability of the pharmaceutical composition may be enhanced by freezing the composition after filling the vial and removing the water under vacuum, (e.g., freeze drying the composition) .
- Parenteral suspensions may be prepared in substantially the same manner, except that the compound should be suspended in the vehicle rather than being dissolved, and, further, sterilization is not achievable by filtration.
- the compound may be sterilized, however, by exposing it to ethylene oxide before suspending it in the sterile vehicle.
- a surfactant or wetting solution may be advantageously included in the composition to facilitate uniform distribution of the compound.
- compositions of this invention comprise a pharmaceutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. Typically, they contain from about 0.01% to about 99% by weight, preferably from about 10% to about 60% by weight, of a compound of this invention, depending on which method of administration is employed.
- compounds may be used to identify opioid receptors from non-opioid receptors.
- compounds of the invention are radiolabeled e.g. by incorporating 3 H or 14 C within its structure or by conjugation to 125 I.
- Such radiolabeled forms can be used directly to identify the presence of opioid receptors and in particular ⁇ opioid receptors in a receptor population. This can be achieved by incubating membrane preparations with a radiolabeled compound of the invention. The presence and or amount of opioid receptors in the preparation is determined from the difference in membrane- bound radioactivity against a control preparation devoid of opioid receptors.
- radiolabeled forms of the present compounds can be exploited to screen for more potent opioid ligands, by determining the ability of the test ligand to displace the radiolabeled compound of the present invention.
- Methanesulfonyl chloride (0.378 g, 0.255 ml, 3.30 mmol) was added to a solution of 2R-tert-butoxycarbonylamino-5-hydroxy- pentanoic acid benzyl ester (0.900 g, 0.278 mmol) and triethylamine (0.455 g, 0.640 ml, 4.50 mmol) in dichloromethane (50 ml) at 0°C. The mixture was stirred for 30 min. then poured into ice water and extracted with dichloromethane (50 ml) three times. The combined solution was dried over MgS0 4 , filtered, then evaporated to give the desired product as an oil (1.06 g, 95%) .
- BocNH A mixture of imidazole (1.00 g, 15.0 mmol), Nal (0.450 g, 3.00 mmol) and 2R-tert-butoxycarbonylamino-5-methanesulfonyloxy- pentanoic acid benzyl ester (1.06 g, 0.264 mmol) in dry DMF (10 ml) was stirred at 80 °C for 3 hr. and then cooled to ambient temperature. The DMF was evaporated and the residue was partitioned between ethylacetate and saturated NaHC0 3 aqueous solution. The organic phase was washed with brine, dried over MgS0 4 , filtered, and evaporated to yield the desired product as oil (0.830 g, 84%) .
- Step 1 2R- [2S-tert-butoxycarbonylamino-3- (4-tert-butoxy- phenyl) -propionylamino] -5-imidazol-l-yl-pentanoic acid benzyl ester
- Boc-S-Tyr (t-Bu) -OH (0.840 g, 2.22 mmol) in dichloromethane (20 ml) was cooled to 0°C (N 2 atmosphere), and triethylamine (0.337 g, 0.464 ml, 3.33 mmol) was added, then isobutyl chloroformate (0.273 g, 0.260 ml, 2.00 mmol) was added. The reaction mixture was stirred for 1 hr. 2-R-amino-5-imidazol-l-yl-pentanoic acid benzyl ester (1.07 g, 2.15 mmol) was added. The reaction mixture was warmed to room temperature and stirred for another hour.
- Step 4 ⁇ 2- (4-tert-butoxy-phenyl) -IS- [IR- ( IS-carbamoyl-2 -phenyl- ethylcarbamoyl) -4-imidazol-l-yl-butylcarbamoyl] -ethyl ⁇ -carbamic acid tert-butyl ester
- Step 5 2R- [2S-amino-3- (4-hydroxy-phenyl) -propionylamino] -5- imidazol-1-yl-pentanoic acid (lS-carbamoyl-2-phenyl-ethyl) -amide (BCH 6377)
- Step 3 2R- [2-amino-3- (4-hydroxy-2 , 6-dimethyl-phenyl) - propionylamino] -5-imidazol-l-yl-pentanoic acid (lS-carbamoyl-2- phenyl-ethyl) -amide
- Step 2 [4- (2-nitro-imidazol-l-yl) -1- (3 -phenyl-propylcarbamoyl) - butyl] -carbamic acid tert-butyl ester
- Step 4 ⁇ 2S- (4 -hydroxy-phenyl) -IR- [4- (2-nitro-imidazol-l-yl-l- (3 -phenyl-propylcarbamoyl) -butylcarbamoyl] - ethyl ⁇ -carbamic acid tert-butyl ester
- the residue was purified by HPLC using a gradient A/B (0 to 70/30) ( A: 0.1% (v/v) TFA aqueous, B: 0.1% (v/v) acetonitrile), followed by lyophilization of aqueous solution to give the desired product as white powder (0.250 g, 83%) .
- Boc-R-Arg(Z 2 ) -OH (0.500 g, 1.01 mmol) in dichloromethane (10 ml) was cooled to 0°C (N 2 atmosphere) and triethylamine (0.123 g, 0.169 ml, 1.21 mmol) was added.
- isobutyl chloroformate (0.137 g, 0.130 ml, 1.01 mmol) was added dropwise and the reaction mixture stirred for 1 hr at this temperature.
- 3-Phenylpropylamine (0.150 g, 0.158 ml, 1.11 mmol) was added dropwise and this mixture was stirred for 1 hr at and then allowed to warm to room temperature and stirred for another 1 hr.
- Boc-R-Arg(Z 2 ) -PPA (0.600 g, 0.909 mmol) was dissolved in TFA/CH 2 C1 2 (1:1) (10 ml). The solution was stirred at room temperature for 1 hr. The solvent was evaporated. The residue was dissolved in ethyl acetate ( 30 ml), washed with sat. NaHC0 3 aqueous solution (50 ml) and brine (30 ml), dried over Na 2 S0 4 , filtered, and the filtrate was evaporated to yield the desired product as an oil (0.504 g, 99%)
- Boc- (RS)2, 6-Me 2 Tyr-R-Arg(Z 2 ) -PPA (2.48 g, 2.91 mmol) was dissolved in methanol (30 ml) . Pd/c (0.31 g) was added. The solution was stirred under hydrogen at room temperature for 1 hr. and the catalyst was filtered off. The filtrate was evaporated to give the desired product as a white solid (1.60 g, 95%) .
- Boc- (RS) 2, 6-Me 2 Tyr-R-Arg-PPA (1.60 g, 2.75 mmol) was dissolved in TFA/CH 2 C1 2 (1:1) (10 ml). The solution was stirred at room temperature for 1 hr. then the solvent evaporated to yield the desired product as white solid. The product was purified by HPLC (C-18) using a 20-50% acetonitrile (0.1% (v/v) TFA) /aqueous ( 0.1% (v/v) TFA) gradient elution to give the two product diastereomers.
- diastereomer fast is the fast moving compound (0.725 g) while diastereomer slow is the slower moving (0.687 g) (overall yield, 71%) .
- the synthetic peptide was prepared using Knorr resin functionalized with the relevant C-terminal N- Fmoc-amino acid residue (phenylalanine) . All amino acids had their alpha amino group Fmoc protected and the following side chains: Pmc for [D] arginine and tBu for tyrosine.
- Dimethylformamide was of American Chemical Standards grade purity and used without further purification.
- TFA was of biograde purity.
- H 2 0 and acetonitrile were HPLC grade solvents. All remaining solvents were of A.C.S. grade purity and used as such without any purification.
- All Fmoc protected amino acids were obtained from Genzyme Pharmaceuticals or Novabiochem USA.
- Solid phase peptide synthesis was carried out manually on Knorr resin. Resin loading was in the order of 0.84 mmoles/g and synthesis was performed on a 3.36 mM scale. Peptide condensation was carried out using 2 equivalents each of Fmoc-AA, HOBT, BOP or DCC and 4 equivalents of N-methylmorpholine (with BOP) in DMF for 2-18 hours at room temperature. The N- Fmoc deprotections steps were carried out using 20% (v/v) piperidine in DMF for 25 minutes .
- TFA containing scavenger (cocktail- 55/2.5/2.5/40 TFA/anisole/EDT/DCM for 90 minutes at room temperature under nitrogen) .
- the solvents were removed by evaporation and the peptide precipitated from diethyl ether, filtered, air dried and then dissolved in 10% (v/v) acetic acid/water and lyophilized.
- the crude peptide was purified and analyzed by HPLC on a reversed phase column (Vydac, 10 micron, 300A) using a flow rate of 9 ml/min with a gradient elution using water plus 0.06% TFA and acetonitrile plus 0.06% TFA in a 0-100% gradient over 80 minutes.
- the pure fractions were combined and lyophilized giving the pure peptide in the trifluoroacetic acid salt form.
- the acid (1.82 g, 6.52 mmol), DBU (974 ⁇ L, 6.52 mmol) and benzylbromide (1.70 mL,9.77mmol) m benzene (40 mL) were heated at reflux for 3h.
- the DBUxHBr was filtered and washed with AcOEt (400 mL) .
- the organic layer was washed with sat NaHC0 3 (1x50 mL) , citric acid (0.5M) (1x50 mL) , H 2 0 (lx 50 mL) , brine and dried over MgS0 4 .
- the crude materill was purified by a flash chromatography (AcOEt/Hex, 1:4) to give the desired product (2.29 g, 96%).
- the solution was diluted with AcOEt (400 mL) and washed with saturated NaHC0 3 (2x 50 mL) , H 2 0(lx 50 mL) , brine (lx 50 mL) and dried over MgS0 4 .
- the product was purified by flash chromatography (MeOH/CH 2 Cl 2 /NEt 3 , 3:95:2) (446 mg of 1 and 895 mg of 2) .
- the solution was diluted with AcOEt (400 mL) and washed in sequence with saturated NaHC0 3 (2x 50 mL) , H 2 0 (lx 50 mL) , citric acid (2x 50 mL) , H 2 0 (lx 50 mL) , brine (2x 50 mL) and dried over MgS0 4 .
- the product was purified by flash chromatography (AcOEt/Hex, 3:5 to 1:1) (198 mg, 64%)
- Boc-D-Arg (Z 2 ) -L- (2-amino-3-phenyl-l-propanol) (0.350 g, 0.504 mmol) was dissolved in TFA/CH 2 C1 2 (1:1) (10 mL) . The solution was stirred at room temperature for 1 hr. The solvent was evaporated. The residue was dissolved in ethyl acetate, washed with sat. NaHC0 3 aqueous solution and brine, dried over Na 2 S0 4 , filtered, and thye filtrate was evaporated to yield the desired product as oil (0.320 g, 97%).
- MOMO-DMT(N 3 ) - D-Arg(Z 2 ) -L- (2-amino-3-phenyl-l-propanol) (0.200 g, 0.244 mmol) was dissolved in methanol (10 ml). Pd/C (0.015 g) was added. The solution was stirred under hydrogen for 2 hr. Catalyst was filtered off. the filtrate was evaporated. The residue was dissolved in TFA/CH2C12 (1:1, 5 ml) and stirred for 30 min. Solvent was evaporeted.
- the residue was purified by HPLC using a gradient A/B (0 to 50%) ( A: 0.1% (v/v) TFA aqueous, B: 0.1% (v/v) acetonitrile), followed by lyphylination of aquous solution to give the desired product as white powder (0.150 g, 85%) .
- Boc-D-Arg(Z2) -L-Phe-OBzl (0.700 g, 0.878 mmol) was dissolved in TFA/CH 2 C1 2 (1:1) (10 mL) . The solution was stirred at room temperature for 1 hr. The solvent was evaporated. The residue was dissolved in ethyl acetate, washed with sat. NaHCO, aqueous solution and brine, dried over Na 2 S0 4 , filtered, and thye filtrate was evaporated to yield the desired product as oil (0.57 g, 95%) .
- MOMO-DMT(N3) - D-Arg (Z2 ) -L-Phe-OBzl (0.60 g, 0.638 mmol) was dissolved in methanol (10 ml). Pd/C (0.068 g) was added. The solution was stirred under hydrogen for 2 hr. Catalyst was filtered off. the filtrate was evaporated. The residue was dissolved in TFA/CH2C12 (1:1, 5 ml) and stirred for 30 min. Solvent was evaporeted.
- the residue was purified by HPLC using a gradient A/B (10 to 50%) ( A: 0.1% (v/v) TFA aqueous, B: 0.1% (v/v) acetonitrile) , followed by lyphylination of aquous solution to give the desired product as white powder (0.220 g, 45%) .
- BocNH y « ⁇ - OBn
- Step 3 2S- ⁇ 3-[2R-Amino-3- (4-methoxymethoxy-2 , 6-dimethyl- phenyl) -propionylamino]-2R-methyl-propionylamino ⁇ -3- phenyl-propionic acid
- the product was purified by HPLC (C-18) using a 20- 70% acetonitrile (0.1% (v/v) TFA) /aqueous ( 0.1% (v/v) TFA) gradient elution, lyophylization of the aqueous solution to give the desired product as white powder (0.171 g, 55%) .
- the product was purified by HPLC (C-18) using a 20- 50% acetonitrile (0.1% (v/v) TFA) /aqueous ( 0.1% (v/v) TFA) gradient elution, lyophylization of the aqueous solution to give the desired product as white powder (0.250 g, 64%) .
- Step 1 To a solution of D-Homophenylalanine (1.005g, 5.67 mmol) in dioxane (8mL) and H 2 0 (10 mL) was added the triethylamine (1.6 mL, 11.34 mmol) and the (Boc) 2 0 (1.49g, 6.81 mmol) . The mixture was stirred at room temperature for over night. The solution was diluted with AcOEt (20 mL) , the aqueous layer was acidified with HCl 10%, then washed with AcOEt (3x200 mL) . The organic layer was washed with H 2 0 (2x50 mL) , brine (2x50 mL) , dried over MgS0 4 and evaporated. The crude compound was used without any futher purification (1.467g, 93%).
- Step 2 The Boc-D-HomoPhe-OH (1.46 g, 5.25 mmol), DBU (0.785 mL, 10.5 mmol) and ethylbromide (0.785 mL,10.5 mmol) in benzene (10 mL) were heated at reflux for 3h.
- the DBUxHBr was filterated and washed with AcOEt (200 mL) .
- the organic layer was washed with sat. NaHC0 3 (1x50 mL) , citric acid (0.5M)(lx50 mL) , H 2 0 (lx 50 mL) , brine and dried over MgS0 4 .
- the desired product was obtained after evaporation of the solvent (1.44 g, 89%).
- Step 3 To a solution of Boc -D-HomoPhe-OEt (1.43g, 4.67 mmol) in dioxane (22mL) at 0 °C was added the ethylmethylsulfide (1.5 mL) and HCl (4M in dioxane) (10 L) . The solution was stirred at 0 °C for 30 min then was allowed to rt .. The volatile was removed and the yellow solid was dried in vacuo for 3h. (1.16 g, 100%).
- Step 4 To a solution of H-D-HomoPhe-OEt HCl salt (425 mg, 1.74 mmol), Boc-D-Arg(N0 2 ) -OH (505 mg, mmol) in DMF (10 mL) was added the 2 , 4 , 6-collidine (1.2 mL, 9.0 mmol) and HATU (1.368 g, 3.6 mmol) at 0 °C. After 30 min at 0 °C, the solution was stirred at rt .
- Step 5 To a solution of Boc -D-arg-D-HomoPhe-OEt (0.822 g, 1.62 mmol) in dioxane (4 mL) at 0 °C was added the ethylmethylsulfide (1.0 mL) and HCl (4M in dioxane) (4 mL) . The solution was stirred at 0 °C for 30 min then was allowed to rt .. The volatile was removed and the yellow solid was dried in vacuo for 3h. (0.721 g, 100?
- Step 6 To a solution of H-D Arg- (N0 2 ) -D-HomoPhe-OEt HCl salt (721 mg, 1.62 mmol), (N 3 ) -DMT- (MOM) -OH (452 mg, 1.62 mmol) in DMF (5 mL) was added the 2 , 4, 6 -collidine (1.3 mL, 9.72 mmol) and HATU (1.23 g, 3.24 mmol) at 0 °C.
- Step 7 To a solution of (N 3 ) -DMT- (MOM) -D Arg- (N0 2 ) -D-HomoPhe-Oet (322 mg, 0.5 mmol) in THF (5 mL) at 0 °C was added a solution of LiOH ( 83 mg, 1.98 mmol) in water (5 mL) . The resulting mixture was stirred for lh at 0°C. The solution was acidified with HCl 10%, then washed with AcOEt (2 x 60 mL) . The organic layer was washed with brine , dried over MgS0 4 .
- Step 8 To a solution of (N 3 ) -DMT- (MOM) -D Arg- (N0 2 ) -D-HomoPhe-OH ( 320 mg, 0.5 mmol) in EtOH/ HOAc (4 :1 mL) was added the Pd/C (40 mg) . The compound was hydrogenated at 45 psi for 36 h. The catalyst was filtered on celite, washed with EtOH and evaporated with toluene.
- Step 9 To a solution of -DMT- (MOM) -D Arg--D-HomoPhe-OH ( 0.34 mmol) in dioxane (5 mL) was added the EtSMe (1.0 mL) and the HCl (4M in dioxane) (1.0 mL) . The solution was stirred at romm temperature for 2h, then the solvant was removed under vaccum. The crude material was purified by
- Step 1 To a solution of (N 3 ) -DMT- (MOM) -D Arg- (N0 2 ) -D-HomoPhe- Oet, obtained as shown in steps 1 to 6 of example 17, ( 237 mg, 0.35 mmol) in EtOH/ HOAc (4 :1 mL) was added the Pd/C (30 mg) . The compound was hydrogenated at 45 psi for 24 h. The catalyst was filtered on celite, washed with EtOH and evaporated with toluene.
- Step 2 To a solution of -DMT- (MOM) -D Arg--D-HomoPhe-OEt ( 209 mg, 0.35 mmol) in dioxane (5 mL) was added the EtSMe (1.0 mL) and the HCl (4M in dioxane) (1.0 mL) . The solution was stirred at room temperature for 2h, then the solvant was removed under vaccum. The crude material was purified by HPLC reversed phase.
- Step 1 To a solution of (N 3 ) -DMT- (MOM) -D Arg- (N0 2 ) -L-HomoPhe-Oet (367 mg, 0.54 mmol), obtained in a similar manner as in Example 17, in THF (5 mL) at 0 °C was added a solution of LiOH ( 92 mg, 2.19 mmol) in water (5 mL) . The resulting mixture was stirred for lh at 0°C. The solution was acidified with HCl 10%, then washed with AcOEt (2 x 60 mL) . The organic layer was washed with brine, dried over MgS0 4 .
- Step 2 To a solution of (N 3 ) -DMT- (MOM) -D Arg- (N0 2 ) -D-HomoPhe-OH ( 320 mg, 0.5 mmol) in EtOH/ HOAc (4 :1 mL) was added the Pd/C (40 mg) . The compound was hydrogenated at 45 psi for 36 h. The catalyst was filtered on celite, washed with EtOH and evaporated with toluene .
- Step 3 To a solution of -DMT- (MOM) -D Arg-L-HomoPhe-OH (0.285 g, 0.5 mmol) in dioxane (5 mL) was added the EtSMe (1.0 mL) and the HCl (4M in dioxane) (1.0 mL) . The solution was stirred at room temperature for 2h, then the solvant was removed under vaccum.
- Affinity for ⁇ and ⁇ opioid receptors was assessed in vitro using radioligand binding assay employing rat brain membrane preparations as described in Schiller et al . , Biophvs . Res . Commun.. 85, p.1322 (1975) incorporated herein by reference.
- Male Sprague-Dawley rats weighing between 350-450g were sacrificed by inhalation of C0 2 .
- the rats were decapitated and the brains minus cerebellum were removed and place in ice-cold saline solution and then homogenized in ice-cold 50 mM Tris buffer pH 7.4 (lOml/brain) .
- the membranes were centrifuged at 14000 rpm for 30 min.
- Radioligand 50 ⁇ l , membranes 100 ⁇ l and serially diluted test compound were incubated for 1 hr at 22 °C. Non specific binding was determined using 500 fold excess of unlabeled ligand in the presence of tracer and membranes. Free ligand was separated from bound by filtration through Whatman GF/B paper (presoaked in polyethylenimine 1% aqueous solution) and rinsing with ice-cold 50mM Tris pH 7.4 using a Brandel cell harvester.
- the filters were dried and radioactivity was counted in a 24 well microplate in the presence of 500 ml scintillant per well. Radioactivity was measured using a Wallac 1450 Microbeta counter. Inhibition constants (K.) for the various compounds were determined from the IC 50 according to the Cheng and Prusoff equation.
- PBQ phenyl-p-benzoquinone
- ED50 values dose of compound which induced a 50% reduction in the number of writhes observed compared to the control
- PBQ solution was prepared by dissolving 20mg of PBQ in 5ml ethanol 90% (sigma, reagent, alcohol) .
- the dissolved PBQ was slowly added to 95ml of distilled water continuously shaken and preheated (not boiled) .
- the PBQ solution was left 2 hours before use, and at all times, protected from light. A new solution was prepared every day for the test.
- mice Central analgesic activity was determined by the inhibition of a hot-plate response in mice according to the experimental protocol described in G. Woolfe and A. Macdonald, J. Pharmacol. Ex . Ther .. 80, p.300 (1944) which is incorporated herein by reference.
- CD #1 male mice weighing between 20 and 25g were weighed, marked, and divided into groups of 10.
- the mice were treated by subcutaneous injection of the compound (or the standard or the medium) in an injection volume equivalent to 0.1 ml/lOg p.c. (lOml/kg) .
- the mice were individually evaluated for reaction time on the hot plate at intervals between 15 minutes and 4 hours after administration of compound.
- the temperature of the hot plate (Sorel, model DS37) was set at 55°C.
- mice were observed for signs of discomfort such as licking or shaking of the paws, attempting to escape (jumping off the plate) or trembling.
- the reaction time was counted when one of these signs appeared and was noted in "seconds". Mice were limited to a maximum period of 30 seconds on the plate so as to prevent damage to paw tissue.
- the average reaction time of the control group was multiplied by 1.5.
- the reaction time of each treated mouse was compared to the "control average X 1.5". If the reaction time was inferior to the "control average X 1.5", the mouse was considered to not have had an analgesic effect. If the reaction time was superior to the "control average X 1.5", then the mouse was considered to have had an analgesic effect.
- the number of analgesic mice in a group determined the analgesic percentage of the compound for this reading. If the analgesic percentage was inferior to 30%, the compound was considered inactive.
- the ED50 dose of drug required to increase latency of response 2 fold compared to control was determined by parallel-line probit analysis.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU74616/98A AU7461698A (en) | 1997-05-07 | 1998-05-05 | Analgesic peptidomimetic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9701718-0 | 1997-05-07 | ||
SE9701718A SE9701718D0 (en) | 1997-05-07 | 1997-05-07 | Analgesic peptidomimetic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998050421A1 true WO1998050421A1 (en) | 1998-11-12 |
Family
ID=20406865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE1998/000826 WO1998050421A1 (en) | 1997-05-07 | 1998-05-05 | Analgesic peptidomimetic compounds |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU7461698A (en) |
SE (1) | SE9701718D0 (en) |
WO (1) | WO1998050421A1 (en) |
ZA (1) | ZA983813B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226991B1 (en) * | 1999-03-23 | 2007-06-05 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Phenylalanine derivatives |
US7825216B2 (en) | 1999-03-23 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Phenylanine derivatives |
US20120329724A1 (en) * | 2010-02-25 | 2012-12-27 | Pfizer Limited | Peptide analogues |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0755942A1 (en) * | 1994-03-11 | 1997-01-29 | Daiichi Pharmaceutical Co., Ltd. | Peptide derivative |
WO1997007130A1 (en) * | 1995-08-18 | 1997-02-27 | Astra Aktiebolag | Novel opioid peptides |
-
1997
- 1997-05-07 SE SE9701718A patent/SE9701718D0/en unknown
-
1998
- 1998-05-05 WO PCT/SE1998/000826 patent/WO1998050421A1/en active Application Filing
- 1998-05-05 AU AU74616/98A patent/AU7461698A/en not_active Abandoned
- 1998-05-06 ZA ZA983813A patent/ZA983813B/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0755942A1 (en) * | 1994-03-11 | 1997-01-29 | Daiichi Pharmaceutical Co., Ltd. | Peptide derivative |
WO1997007130A1 (en) * | 1995-08-18 | 1997-02-27 | Astra Aktiebolag | Novel opioid peptides |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7226991B1 (en) * | 1999-03-23 | 2007-06-05 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Phenylalanine derivatives |
US7825216B2 (en) | 1999-03-23 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Phenylanine derivatives |
US20120329724A1 (en) * | 2010-02-25 | 2012-12-27 | Pfizer Limited | Peptide analogues |
EP2539358A1 (en) * | 2010-02-25 | 2013-01-02 | Pfizer Limited | Peptide analogues |
US8598123B2 (en) * | 2010-02-25 | 2013-12-03 | Pfizer Inc. | Peptide analogues |
Also Published As
Publication number | Publication date |
---|---|
SE9701718D0 (en) | 1997-05-07 |
ZA983813B (en) | 1998-11-09 |
AU7461698A (en) | 1998-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2126418C1 (en) | Endothelin receptor antagonists | |
JP3311392B2 (en) | Novel orally active elastase inhibitors | |
EP0914332B1 (en) | Isoquinolines useful as analgesics | |
NO861141L (en) | PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITIES N, N [-DIALKYLGUANIDINO DIPEPTIDES. | |
JPH10502078A (en) | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase | |
JP2000501382A (en) | Novel amino acid derivatives, their preparation methods and pharmaceutical compositions containing these compounds | |
AU673497B2 (en) | Anti-thrombotic peptides and pseudopeptides | |
AU733591B2 (en) | Stable non-hygroscopic crystalline form of N-(N-N-(4-(piperidin-4-yl)butanoyl)-N-ethylglycyl) compounds | |
WO2006050861A2 (en) | Statine derivatives for the treatment of alzheimer's disease | |
US20020022621A1 (en) | Benzodiazepinone beta -amyloid inhibitors: arylacetamidoalanyl derivatives | |
US5332726A (en) | Antithrombotic peptides and pseudopeptides | |
US20060025345A1 (en) | Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease | |
WO2007014946A1 (en) | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii | |
JP2001501965A (en) | Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides | |
EP1845104A1 (en) | Par-2 agonist | |
JPH11514378A (en) | Thrombin inhibitor | |
WO1998050421A1 (en) | Analgesic peptidomimetic compounds | |
HU185229B (en) | Process for preparing pharmaceutically active peptides and acetates thereof | |
JPH08503920A (en) | Antithrombotic peptide and pseudopeptide derivative | |
JPH09511743A (en) | Peptide segment condensation method | |
AU2003218401A1 (en) | Immunosuppressant compounds, methods and uses related thereto | |
JPWO2003082819A1 (en) | N-phenyl-N- (4-piperidinyl) amide derivatives | |
HU206369B (en) | Process for producing di- and tripeptides stimulating the immune system | |
JPH10330398A (en) | New cyclic peptide | |
EP1864994A1 (en) | Par-2 agonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09180940 Country of ref document: US |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998547977 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |